Introduction: Hepatitis C virus infection is one of the leading causes of chronic liver disease
worldwide, as approximately 85% of acute HCV infections progress to chronicity, with an
insidious, slowly evolving progressive. Complications include cirrhosis and hepatocellular
carcinoma. Thus, the goal of drug therapy is to cure HCV infection to prevent hepatic and
extra-hepatic complications related to disease. Objective To describe the epidemiological
profile of patients with chronic hepatitis C, besides investigating the main clinical outcomes
and the results obtained after treatment. Methodology:
It is an observational study of a historical cohort evaluating data from medical records. The
sample was randomly selected and evaluated for inclusion and exclusion criteria. The data
obtained were recorded in a database built in Microsoft Office Access and in the analysis
were applied descriptive and inferential statistical methods. Results and Discussion: There
were 108 patients evaluated, predominantly male (55.6%). Regarding age, the minimum and
maximum were 35 and 85 years, respectively, with a mean of 60.7 years (SD + - 12.2 years).
Of these, 57.4% had at least one comorbidity, with a higher prevalence of hepatic steatosis
(27.8%). Among genotypes, genotype 1b (45.4%) was more frequent, followed by G3, G1a
and G2 with prevalences of 28.7%, 20.4% and 3.7%, respectively. Of the total, 95.4% had
their degree of fibrosis evaluated, finding a higher prevalence of grade 4 fibrosis (44.4%). In
these patients, the complications were portal hypertension 47.9%, ascites (25%) and hepatic
encephalopathy (6.25%). Of the cases, 75.9% were treated, in those patients the most used
antiretroviral regimen was Sofosbuvir + Daclatasvir (30.5%) and the most frequent treatment
time was 12 weeks (83%). Considering the response pattern presented, it can be seen that
76.8% did not have CRP at the end of treatment, but among the 19 cases recorded the SVR
was 84.2%.Conclusion: The results obtained demonstrated similarities with the national and
international literature regarding the epidemiological profile of chronic HCV patients.
Regarding the treatment, in spite of the scarce data it was possible to demonstrate the high
rate of SVR in the appropriately treated group and that the post-treatment follow-up with the
CRP dosing.
|
